Malaria vaccine being developed in DelhiApril 24th, 2009 - 2:52 pm ICT by ANI
New Delhi, Apr 24 (ANI): Scientists are undertaking research to develop a vaccine for immunization against malaria. The vaccine is expected to reduce the severity of the disease.
The scientists at the international Institute of Genetic Engineering and Biotechnology (ICGEB) in New Delhi are involved in the research on malaria for the past few years.
The scientists at the institute have tested almost 20 vaccines. One of them is showing good results.
The scientists believe the progress of the research of the vaccine depends on the phase one trial. If this goes on well, the scientists expect to develop a partially successful vaccine to reduce the severity of the disease in a few years.
“I think if everything goes well, we may have a partially successful working vaccine in the next five to ten years. If other efforts also go simultaneously and if there are several partially successful vaccines, they can be mixed together to get a much better vaccine. We are in the beginning of the malaria vaccine research,” said Dr. V.S Chauhan, director, ICGEB.
The vaccine for malaria will not work as other vaccines. The centre is developing a vaccine for infants initially. It will boost the immunity of children to fight against the disease.
“In this case, the initial aim would be just to immunize very young children, infants, in the areas where there is a lot of malaria and just boost their immunity artificially a little more. Children will still get malaria, but they will not die of the disease. In other words, the severity of the disease will be hugely reduced. So that they get exposure but they do not die. After two or three exposures, they themselves become immune to malaria infection,” added Dr. Chauhan.
The ICGEB has collaborated with industrial partners and is receiving funds from the government to carry on the research.
The research includes developing a vaccine, which prohibits the entry of the malaria parasite into the red blood cells.
“We are trying to focus on blocking the entry of the parasite into the red blood cells. If we are successful, then the parasite will not enter the red blood cells. Hopefully, it will not let the disease happen. So, we will still get the disease but the severity of the disease will go extremely down. So that way the death rate we are targeting is 0,” said Dr. S. Shams Yazdani, a scientist at the ICGEB laboratory.
Malaria is a vector borne infectious disease caused by a parasite called Plasmodium transmitted by infected mosquitoes. There is yet no completely successful vaccine for malaria. (ANI)
- Scientists closer to developing anti-malaria shot - Aug 06, 2012
- Scientists locate malaria parasites' Achilles heal - Apr 22, 2012
- Breakthrough may pave way for new malaria drugs - Nov 27, 2011
- Protein group prime candidate for potent malaria vaccine - Jan 19, 2010
- New discovery paves way for effective malaria vaccine - Jun 18, 2010
- Vaccine slashes malaria risk by half - Jan 14, 2011
- Re-engineering mosquito's immunity to block malaria - Dec 29, 2011
- Scientists isolate key to malaria's 'invisibility cloak' - Jan 19, 2012
- Discovery could lead to 'next-gen' vaccines - Apr 08, 2012
- Mosquitoes themselves may one day become anti-malaria `syringes' - Aug 30, 2010
- Blood-thinning drug can stop malaria infection - Jun 02, 2010
- New strategy for developing 'next-generation' malaria vaccines - Nov 03, 2009
- Now, 'needle-free' natural vaccine against malaria - Aug 12, 2010
- How malaria parasites manage to outwit our immune system - Dec 01, 2009
- Modified yellow fever vaccine may help fight malaria - Jun 12, 2010
Tags: biotechnology, exposures, genetic engineering, icgeb, immunity, immunization, industrial partners, initial aim, malaria infection, malaria parasite, malaria vaccine research, New Delhi, phase one, red blood cells, scientists, severity, undertaking research, vaccines